Trial Profile
Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms VOLTAIRE-RAext
- Sponsors Boehringer Ingelheim
- 15 Nov 2023 Results of pooled subgroup analysis from five phase 3 randomized controlled clinical trials (VOLTAIRE-RA , VOLTAIRE-RAext, VOLTAIRE-CD, VOLTAIRE-PsO and VOLTAIRE-X) assessing incidence of safety endpoints in patients with RA )presented at the ACR Convergence 2023
- 03 May 2020 Results published in the British Journal of Clinical Pharmacology
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting